Chief Financial Officer and President · Q32 Bio Inc. (QTTB)

Lee Kalowski

A named executive officer of Q32 Bio in every fiscal year CompBrief holds from FY2024 to FY2025. Every figure below is printed as the company filed it and cited to the filing it came from.

Total disclosed compensation, FY2025

$987,147

Salary $565,000Stock awards $135,255

FY2024: $2,854,009

2nd of 3 named executive officers at Q32 Bio by FY2025 total.

3 named officers on file for Q32 Bio, FY2025

Lee Kalowski’s pay file — $29

  • 2 fiscal years of pay, line by line
  • 1 equity grant, each cited to its filing

A PDF and a CSV sent to your email. Every row is cited to its filing.

One-time report. No refunds.

See an example →

Velarion Intel · free for 3 days · no card

See how Q32 Bio’s whole pay program stands against its peers

  • Q32 Bio’s company dashboard and its AI-written, board-ready brief, every figure cited to the filing
  • Peer-group intelligence, custom peer reruns and governance screens
  • Every other company we cover, with alerts when they file
Start my free trial on QTTB→

No card. Nothing is charged, and the trial ends on its own.

Compensation figures as of the proxy filed April 30, 2026 (DEF 14A). Insider transactions since that proxy, current to 2026-11-21.

Free

Get Lee Kalowski’s full pay file as a PDF — free

More than this page: up to 10 years of Lee’s pay history, a side-by-side peer comparison, and a one-page board summary — the whole file, yours now and by email.

Lee Kalowski compensation by year

Q32 Bio Summary Compensation Table · all 2 fiscal years held
In US dollars, as Q32 Bio reports it. Most recent year shaded. Totals are the company’s disclosed totals.
ComponentFY2024FY2025
Salary$432,442$565,000
Bonus$0$0
Stock awards$0$135,255
Option awards$2,103,216$59,122
Non-equity incentive$146,900$226,000
Pension and deferred compensation$0$0
All other$171,451$1,770
Total$2,854,009$987,147

Each year as stated in that year's proxy. A dash means the company reported no figure in that column. Source: Q32 Bio Inc. DEF 14A filed April 30, 2026, accession 0001193125-26-193934, and prior-year filings. Open the filing on EDGAR.

How this page was built: the Q32 Bio Inc. filed document, accession 0001193125-26-193934. Every figure is read from that document and cited to the page and table it appears in. Filed April 30, 2026.

$2.9M
$987K
FY24
FY25
SalaryNon-equity incentiveStock awardsOption awardsAll other

Equity holdings

unvested awards at FY2025 year-end
TypeUnvested unitsValue at year-endExercise price
RSU39,938$137,387—
Option73,941—$2.54

Per the Outstanding Equity Awards at Fiscal Year-End table in Q32 Bio Inc.'s FY2025 proxy; value at the fiscal year-end close, as the company printed it.

Insider transactions since the last proxy

3 Form 4 lines since the FY2025 proxy (filed April 30, 2026)
current to 2026-11-21 · updated nightly
DateTransactionPlanSharesPriceHeld after
2026-10-06Sale—1,301$8.32137,170
2026-08-25Sale—3,972$16.56138,471
2026-07-16Grant or award—53,250$0.00142,443

The 3 most recent of 3 lines, each as reported on the Form 4. "10b5-1" marks a trade the filing reports under a pre-arranged trading plan. View every Form 4 filing on EDGAR →

Q32 Bio’s named executive officers, FY2025

as the company reported each
Named executive officerRoleFY2025 total
Jodie MorrisonChief Executive Officer and Director$1,558,870
Lee Kalowski · this pageChief Financial Officer and President$987,147
Shelia VioletteChief Scientific Officer$774,446

The full Q32 Bio compensation record

free company brief

This page is one person within Q32 Bio's record. The company brief lists every named executive, each linking to their own page.

Compensation, the day it’s disclosed

The CompBrief Daily Digest lists the newest executive and director compensation disclosures as companies file them.

How this record is built

Every figure on this page is one figure from a public SEC filing, printed as the filing states it and cited to the document. Compensation totals are Q32 Bio's own disclosed totals, not summed by Velarion. Insider transactions are read from Form 4 filings and cover every line filed since the most recent proxy. Nothing is estimated by Velarion; where the company does not disclose a value the cell reads "—", and a section appears only where the company discloses the data. Corrections: records@velarion.ai.

Lee Kalowski's compensation dossier · One-time report. No refunds.